Rock Creek Pharmaceuticals, Inc. is a pharmaceutical company. The Company is specifically focused on research, development, and commercialization of compounds and formulations targeting inflammatory and neurological disorders. The Company is engage in and advance research and clinical development of pharmaceuticals to provide therapeutic solutions. The Company is engaged in vitro and in vivo ability to modulate the expression of specific inflammatory molecules considered relevant to many chronic inflammatory disease states. The Company has conducted in vitro and in vivo toxicological and pharmacological research on lead drug candidates, and poised to begin first Phase 1 clinical trials. The Company’s research area targets are Osteoarthritis, Ulcerative Colitis, Psoriasis, Smoking Cessation, and Hashimoto's Thyroiditis.